FATE PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

FATE ▼ -20.64% at T+5d

LONG call ✗ call lost -20.64% · α vs SPY -20.56% · entry $2.18 → $1.73

Next anchor: T+20d due 4d ago

Currently $2.06 · -5.50% from $2.18 entry

Entry anchored
May 8, 03:59 PM ET
via Databento tick

T+1d

+3.21%

call +3.21% · α +3.35%

$2.25

settled 5w ago

T+5d

-20.64%

call -20.64% · α -20.56%

$1.73

settled 26d ago

T+20d

—

call — · α —

—

due 4d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Fate Therapeutics presented clinical and preclinical data at ASGCT 2026 for its off-the-shelf iPSC-derived CAR T-cell programs. FT819 showed 3/3 SLE patients achieving SRI-4 and 2/3 achieving LLDAS with durable B-cell remodeling up to 12 months without conditioning chemotherapy. Preclinical data for FT839 and FT836 demonstrated broad depletion of pathogenic cells and synergy with standard-of-care therapies. The data supports the company's platform approach to eliminate conditioning chemotherapy, potentially expanding patient access.

Actionable Insight

The FT819 data showing efficacy without conditioning chemotherapy is a significant differentiator in the competitive CAR T landscape. Monitor for additional FT819 dose level 2 data and potential regulatory alignment for registrational path. FT839 and FT836 preclinical data support pipeline optionality but are early stage.

Key Facts

FT819: 3/3 SLE patients achieved SRI-4, 2/3 achieved LLDAS at dose level 1 without conditioning chemotherapy.
FT819: 79% average depletion of major B cell clones lasting up to 12 months post single dose.
FT839 preclinical: >99% depletion of B cells, plasmablasts, plasma cells; >90% depletion of activated T cells in RA and SLE samples.
FT839: Persistence enhanced ~60x vs. unmodified CAR T via Sword and Shield technology.
FT836 preclinical: Up to 100% tumor control in xenograft models as monotherapy or with mAbs; cytolytic activity enhanced ~5x with chemo/radiotherapy.
FT836: Phase 1 clinical trials ongoing in solid tumors (NCT07216105) and multiple myeloma (NCT07221032).
FT819 dose level 2 (900M cells) enrollment initiated.

Financial Impact

No financial figures disclosed in press release. Positive clinical data may support future regulatory filings and partnership opportunities.

clinical trial enrollmentregulatory pathpotential revenue

Risk Factors

Clinical data is early-stage (Phase 1, small sample size) and may not replicate in larger trials.
FT819 dose level 2 data not yet available; higher doses may have safety or efficacy issues.
FT839 and FT836 are preclinical; clinical validation is years away.
Company has no approved products and relies on future financing or partnerships.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

61% bullish (18 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3291886

6 reports for FATE

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for FATE — sortable, filterable
	Type				Now
Jun 11, 2026 1d ago	Institutional Cluster BEARISH ★ 5/10	$1.95 awaiting T+5	awaiting T+5	—	$2.06 (−5.64%)
Jun 4, 2026 8d ago	8-K NEUTRAL ★ 4/10	$2.15 awaiting T+5	awaiting T+5	—	$2.06 (−4.19%)
Jun 1, 2026 12d ago	Press Release BULLISH ★ 6/10	$2.74 $1.98	▼ −27.74%	▼ −24.99%	$2.06 (−24.82%)
May 13, 2026 4w ago	8-K NEUTRAL ★ 5/10	$2.14 $1.89	▼ −11.68%	▼ −10.52%	$2.06 (−3.74%)
May 11, 2026 4w ago	Press Release BULLISH ★ 7/10	$2.18 $1.73	▼ −20.64%	▼ −20.56%	$2.06 (−5.50%)
Apr 24, 2026 7w ago	DEFA14A NEUTRAL ★ 3/10	$1.31 $1.80	▲ +37.40%	▲ +37.00%	$2.06 (+57.25%)

US Market Status

Market Closed — Opens Mon (48h 13m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access